Skip to content

Effect of Parecoxib on Post-craniotomy Pain

Phase Four Study of Intravenous Parecoxib on Post-craniotomy Pain

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00455117
Enrollment
130
Registered
2007-04-03
Start date
2006-09-30
Completion date
2008-12-31
Last updated
2013-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anaesthesia

Keywords

analgesia, pain, neurosurgery, NSAIDS, parecoxib, morphine consumption

Brief summary

Aim of this trial: To investigate whether post-craniotomy analgesia with (i) intravenous (IV) parecoxib plus intravenous paracetamol is superior to (ii) intravenous paracetamol alone. Study Hypothesis: Post-operative analgesia with intravenous parecoxib in combination with intravenous paracetamol will be superior to intravenous paracetamol alone.

Detailed description

Neurosurgical patients undergoing brain procedures (craniotomy patients) are known to suffer moderately severe postoperative pain and high rates of post-operative nausea and vomiting. Post-craniotomy pain is poorly treated with more than 50% of craniotomy patients experiencing postoperative pain of moderate or severe intensity. Fear of drug complications such as sedation, respiratory depression, seizures and intracranial bleeding has inhibited prescribing of effective pain treatment.Non-steroidal anti-inflammatory drugs (NSAIDS) are known to be effective analgesics in the peri-operative period however there use in cranial neurosurgery has been limited due to risk of bleeding. Parecoxib is an injectable form of NSAID that works through inhibiting cyclo-oxygenase type-2 (COX-2). The main benefit of COX-2 inhibitors is that they have minimal inhibition of platelet function and therefore minimal risk of increased bleeding.This project aims to evaluate whether parecoxib is an effective pain reliever (analgesic) after brain surgery. Patients aged 18-65 years presenting for elective craniotomy will be randomly allocated to two different analgesic programs (i) IV parecoxib and IV paracetamol or (ii) IV paracetamol. All patients will receive a standardised anaesthetic. Scalp infiltration, using 20mls of local anesthetic (bupivacaine 0.5% with adrenaline), will occur prior to skin incision. Intermittent morphine administration will used post-operatively to ensure adequate analgesia in each arm of the trial. Immediate post-operative adjunctive analgesia will be provided with nurse administered IV morphine in the post-anaesthetic care unit (PACU) as per protocol (RMH protocol for opioid titration), followed by patient controlled analgesia (PCA) morphine once the verbal rating scale is \< 4 (rating out of ten). A score of less than four is considered to be mild pain. PCA will be continued for the first twenty-four hours then discontinued. Patients will then receive strict oral paracetamol and nurse administered IV morphine as required. The primary study endpoint will be morphine consumption in the first 24 hours. Data will be analysed on an intention to treat basis. Continuous variables will be graphed to determine their distribution. Normally distributed variables will be described using mean and standard deviation and compared using Student's t-tests. Skewed variables will be described using median and range (or interquartile range) and compared using Wilcoxon rank sum tests. A p-value les than 0.05 will be considered statistically significant.

Interventions

DRUGIntravenous Parecoxib ('Dynastat' Pfizer)

parecoxib or placebo

Sponsors

Melbourne Health
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Supratentorial craniotomy, glasgow coma scale 15

Exclusion criteria

* Chronic pain, * Chronic opioid use. * History of significant alcohol or benzodiazepine (BZD) use, * Inability to speak English, * Pre-operative aphasia or dysphasia, * Renal impairment (Creatinine level \> 0.1), * Asthma (or evidence of reversible airway obstruction, * Known ischaemic heart disease or cerebrovascular disease, * American Society of Anaesthesiologists (ASA) grade IV or V, * Allergy to any study drug (paracetamol, parecoxib, sulphas, morphine, bupivacaine, propofol, remifentanil; * Administration of oral paracetamol within previous 8 hours. * Pregnancy or breastfeeding

Design outcomes

Primary

MeasureTime frame
Morphine consumption in 24 hour period.24 hours after surgery

Secondary

MeasureTime frame
Pain scores at zero (time of extubation), 1, 2, 4, 12, 24 hours post operatively24 hours after surgery
Analgesic efficacy at 24 hours24 hours after surgery
Incidence of post-operative nausea and vomiting (first 24 hours)24 hours after surgery
Sedation or respiratory depression (first 24 hours)24 hours after surgery
Immediate post-operative hypertension (first 2 hours)24 hours after surgery
Post-operative AMI24 hours after surgery
Post-operative renal failure24 hours after surgery
Post-operative thromboembolic stroke24 hours after surgery
Post-operative intracranial haemorrhage24 hours after surgery
Safety Monitoring (Serious adverse side effects)24 hours after surgery

Countries

Australia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026